Acumen Q3 net loss $29.8M; cash $258.9M; ALTITUDE-AD enrollment on track for H1 2025

Acumen Pharmaceuticals, Inc.

2024-Q3 EPS reported -$1.09

Net loss of $29.8M for Q3 2024 vs $13.0M in Q3 2023, driven by higher R&D costs ($27.2M vs $11.2M).
Cash, equivalents and marketable securities of $258.9M as of Sept 30, 2024, expected to fund operations into H1 2027.
Phase 2 ALTITUDE-AD enrollment for sabirnetug expected to complete in first half of 2025.
Topline results from Phase 1 subcutaneous sabirnetug study anticipated in Q1 2025.
Appointed Amy Schacterle, PhD as Chief Regulatory Officer & Head of Quality in November 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.